{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:32:15Z","timestamp":1768876335614,"version":"3.49.0"},"reference-count":86,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2015.00651","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T09:11:06Z","timestamp":1452503466000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes"],"prefix":"10.3389","volume":"6","author":[{"given":"Minh N.","family":"Pham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias G.","family":"von Herrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Vela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12026-013-8452-5","article-title":"The IL-2\/IL-2R system: from basic science to therapeutic applications to enhance immune regulation","volume":"57","author":"Bayer","year":"2013","journal-title":"Immunol Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.urology.2014.02.005","article-title":"High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience","volume":"83","author":"Hanzly","year":"2014","journal-title":"Urology"},{"issue":"3","key":"B5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.critrevonc.2015.07.009","article-title":"Metastatic clear cell renal cell carcinoma: a review of current therapies and novel immunotherapies","volume":"96","author":"Thomas","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/bjc.1983.15","article-title":"Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects","volume":"47","author":"Bindon","year":"1983","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2893.2005.00694.x","article-title":"Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1","volume":"13","author":"Alric","year":"2006","journal-title":"J Viral Hepat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1084\/jem.20100209","article-title":"IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells","volume":"207","author":"Grinberg-Bleyer","year":"2010","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/cei.12629","article-title":"Interleukin-2 treatment reverses effects of cAMP-responsive element modulator alpha-over-expressing T cells in autoimmune-prone mice","volume":"181","author":"Ohl","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1111\/ajt.12944","article-title":"Administration of low doses of IL-2 combined to rapamycin promotes allogeneic skin graft survival in mice","volume":"14","author":"Pilon","year":"2014","journal-title":"Am J Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.2337\/diabetes.51.3.638","article-title":"Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice","volume":"51","author":"Rabinovitch","year":"2002","journal-title":"Diabetes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","article-title":"Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction","volume":"28","author":"Tang","year":"2008","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J Autoimmun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/dmrr.2503","article-title":"GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months","volume":"30","author":"Ludvigsson","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1089\/152091503322641006","article-title":"A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8)","volume":"5","author":"Pozzilli","year":"2003","journal-title":"Diabetes Technol Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","article-title":"Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial \u2013 type 1","volume":"28","author":"Skyler","year":"2005","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/dc09-0449","article-title":"No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes","volume":"32","author":"Walter","year":"2009","journal-title":"Diabetes Care"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12656","article-title":"Factors impeding the discovery of an intervention-based treatment for type 1 diabetes","author":"von Herrath","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B27","first-page":"304","article-title":"Structure and expression of a cloned cDNA for human interleukin-2. 1983","volume":"24","author":"Taniguchi","year":"1992","journal-title":"Biotechnology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1600-065X.1998.tb01246.x","article-title":"Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy","volume":"165","author":"Powell","year":"1998","journal-title":"Immunol Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.052676899","article-title":"Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death","volume":"99","author":"Cheng","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: at the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.jmb.2004.04.038","article-title":"Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors","volume":"339","author":"Rickert","year":"2004","journal-title":"J Mol Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1073\/pnas.0511161103","article-title":"Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor","volume":"103","author":"Stauber","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1126\/science.1117893","article-title":"Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors","volume":"310","author":"Wang","year":"2005","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1073\/pnas.93.5.2077","article-title":"Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation","volume":"93","author":"Friedmann","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B36","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1189\/jlb.1107778","article-title":"The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells","volume":"84","author":"Wuest","year":"2008","journal-title":"J Leukoc Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1002\/eji.1830251111","article-title":"Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells","volume":"25","author":"Sadlack","year":"1995","journal-title":"Eur J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1126\/science.7770771","article-title":"Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta","volume":"268","author":"Suzuki","year":"1995","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.4049\/jimmunol.172.11.6519","article-title":"Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function","volume":"172","author":"Thornton","year":"2004","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.immuni.2010.04.001","article-title":"Etiology of type 1 diabetes","volume":"32","author":"Todd","year":"2010","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.4049\/jimmunol.1100272","article-title":"Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function","volume":"188","author":"Garg","year":"2012","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/db11-1213","article-title":"Central role for interleukin-2 in type 1 diabetes","volume":"61","author":"Hulme","year":"2012","journal-title":"Diabetes"},{"key":"B43","first-page":"242","article-title":"Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications","volume":"73","author":"Kitas","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"740619","DOI":"10.1155\/2010\/740619","article-title":"The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity","volume":"2010","author":"Lieberman","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"B45","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.4049\/jimmunol.130.6.2651","article-title":"Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE)","volume":"130","author":"Linker-Israeli","year":"1983","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1002216","DOI":"10.1371\/journal.pgen.1002216","article-title":"Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases","volume":"7","author":"Plagnol","year":"2011","journal-title":"PLoS Genet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.4049\/jimmunol.1100061","article-title":"IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo","volume":"186","author":"Chen","year":"2011","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s002620050527","article-title":"Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2","volume":"47","author":"Lentsch","year":"1999","journal-title":"Cancer Immunol Immunother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.immuni.2015.04.018","article-title":"Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps","volume":"42","author":"Mitra","year":"2015","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2015.04.015","article-title":"Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms","volume":"42","author":"Spangler","year":"2015","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clim.2014.02.003","article-title":"Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer","volume":"151","author":"Churlaud","year":"2014","journal-title":"Clin Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"issue":"2","key":"B54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.18388\/abp.2009_2469","article-title":"Diminished expression of ICOS, GITR and CTLA-4 at the mRNA level in T regulatory cells of children with newly diagnosed type 1 diabetes","volume":"56","author":"Luczynski","year":"2009","journal-title":"Acta Biochim Pol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00042560-200202010-00006","article-title":"Sustained suppression of HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV\/hepatitis C virus coinfection","volume":"29","author":"Schlaak","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1089\/aid.2007.0180","article-title":"Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV\/HCV-coinfected patients","volume":"24","author":"Velilla","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity","volume":"20","author":"Kennedy-Nasser","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/sj.jidsp.5640212","article-title":"Alopecia areata is a T-lymphocyte mediated autoimmune disease: lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice","volume":"4","author":"Gilhar","year":"1999","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"10","key":"B60","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/1346-8138.12978","article-title":"Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata","volume":"42","author":"Han","year":"2015","journal-title":"J Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/db15-0188","article-title":"Therapeutic window of interleukin-2 for autoimmune diseases","volume":"64","author":"Tang","year":"2015","journal-title":"Diabetes"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.2337\/db14-1322","article-title":"Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes","volume":"64","author":"Yu","year":"2015","journal-title":"Diabetes"},{"issue":"10","key":"B63","doi-asserted-by":"publisher","first-page":"18574","DOI":"10.3390\/ijms151018574","article-title":"Low-dose interlekin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity","volume":"15","author":"Kosmaczewska","year":"2014","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s11892-013-0415-7","article-title":"Antigen-based vaccination and prevention of type 1 diabetes","volume":"13","author":"Harrison","year":"2013","journal-title":"Curr Diab Rep"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.2337\/db10-0630","article-title":"Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential","volume":"59","author":"Peakman","year":"2010","journal-title":"Diabetes"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e54712","DOI":"10.1371\/journal.pone.0054712","article-title":"Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice","volume":"8","author":"Sarikonda","year":"2013","journal-title":"PLoS One"},{"issue":"22","key":"B67","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa012350","article-title":"Effects of insulin in relatives of patients with type 1 diabetes mellitus","volume":"346","author":"Diabetes Prevention Trial \u2013 Type 1 Diabetes Study Group","year":"2002","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/S0140-6736(08)61309-4","article-title":"Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial","volume":"372","author":"Nanto-Salonen","year":"2008","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1365-2249.2008.03814.x","article-title":"Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study","volume":"155","author":"Thrower","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/jama.2015.2928","article-title":"Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial","volume":"313","author":"Bonifacio","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"B71","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/dmrr.691","article-title":"Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients","volume":"23","author":"Huurman","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"B72","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1365-2249.2008.03656.x","article-title":"Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes","volume":"152","author":"Huurman","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"9295","key":"B73","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(01)06801-5","article-title":"Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial","volume":"358","author":"Raz","year":"2001","journal-title":"Lancet"},{"issue":"7","key":"B74","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/dmrr.1126","article-title":"Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65)","volume":"26","author":"Axelsson","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"B75","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa1107096","article-title":"GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus","volume":"366","author":"Ludvigsson","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"B76","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.clim.2010.10.004","article-title":"GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients","volume":"138","author":"Hjorth","year":"2011","journal-title":"Clin Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4161\/hv.26890","article-title":"Non-antigenic and antigenic interventions in type 1 diabetes","volume":"10","author":"Ryden","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B78","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/dmrr.2643","article-title":"Heterogeneity in recent-onset type 1 diabetes \u2013 a clinical trial perspective","volume":"31","author":"Bollyky","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.2337\/db11-1538","article-title":"Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data","volume":"61","author":"Greenbaum","year":"2012","journal-title":"Diabetes"},{"key":"B80","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2337\/db13-0881","article-title":"Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial","volume":"63","author":"Lachin","year":"2014","journal-title":"Diabetes"},{"issue":"21","key":"B81","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1056\/NEJM198605223142106","article-title":"Type I diabetes mellitus. A chronic autoimmune disease","volume":"314","author":"Eisenbarth","year":"1986","journal-title":"N Engl J Med"},{"issue":"1","key":"B82","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00125-015-3752-z","article-title":"The influence of type 1 diabetes on pancreatic weight","volume":"59","author":"Campbell-Thompson","year":"2016","journal-title":"Diabetologia"},{"issue":"2","key":"B83","first-page":"98","article-title":"Biomarkers for type 1 diabetes","volume":"1","author":"Purohit","year":"2008","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"B84","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.clim.2015.05.021","article-title":"Immunotherapies and immune biomarkers in Type 1 diabetes: a partnership for success","volume":"161","author":"Rekers","year":"2015","journal-title":"Clin Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/MED.0000000000000076","article-title":"Biomarkers in type 1 diabetes: application to the clinical trial setting","volume":"21","author":"Tooley","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"B86","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.clim.2015.05.023","article-title":"Biomarkers for antigen immunotherapy in allergy and type 1 diabetes","volume":"161","author":"Odegard","year":"2015","journal-title":"Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T12:37:44Z","timestamp":1692189464000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fimmu.2015.00651\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":86,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2015.00651","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,11]]}}}